Celgene Corporation (CELG)
-NasdaqGS 119.26 
2.60(2.23%) 4:00PM EDT|After Hours
:
119.25 0.01 (0.01%) 7:20PM EDT
| Prev Close: | 116.66 |
|---|
| Open: | 116.23 |
|---|
| Bid: | 108.00 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 124.69 |
|---|
| Beta: | 0.92 |
|---|
| Next Earnings Date: | 25-Jul-13 |
|---|
| Day's Range: | 114.05 - 119.57 |
|---|
| 52wk Range: | 58.53 - 128.52 |
|---|
| Volume: | 3,345,238 |
|---|
| Avg Vol (3m): | 3,218,760 |
|---|
| Market Cap: | 49.94B |
|---|
| P/E (ttm): | 36.28 |
|---|
| EPS (ttm): | 3.29 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Biotechnology companiesAP(Thu 6:05PM EDT)
- [video] Cramer on the Action In Europeat CNBC(Thu 6:00PM EDT)
- Top Fund Buys Focus On Defensive Stocks, Housingat Investor's Business Daily(Thu 5:45PM EDT)
- Wider-Than-Expected Loss at PharmacyclicsZacks(Thu 1:30PM EDT)
- Midday Glance: Biotechnology companiesAP(Thu 1:25PM EDT)
- Does Celgene Still Have Upside Potential?at Wall St. Cheat Sheet(Thu 12:28PM EDT)
- Are These The Biotech Stars Of Tomorrow?The StreetAuthority Network(Thu 11:00AM EDT)
- Can This Biotech Soar Again?at Motley Fool(Wed, May 1)
- Early Glance: Biotechnology companiesAP(Wed, May 1)
- 4 Bio Stocks to Buy Todayat Motley Fool(Wed, May 1)
- Analysts: Microsoft’s Cloud Beating Expectations and 3 Other Research Notes to Browseat Wall St. Cheat Sheet(Tue, Apr 30)
- Wall Street Transcript Interview with Ian Somaiya, Managing Director and Senior Research Analyst at Piper Jaffray & Co.: Identifying Hidden Value and Market Opportunities in Biotech CompaniesWall Street Transcript(Tue, Apr 30)
- CELGENE CORP /DE/ Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, Apr 30)
- The Zacks Analyst Blog Highlights: Merck, GlaxoSmithKline, VIVUS, Santarus and CelgeneZacks(Tue, Apr 30)
- [$$] Credits & Debits | cfoeditors@wsj.comat The Wall Street Journal(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | 17.38 |
|---|
| P/S (ttm): | 8.57 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.71 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.42 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 0.94 |
|---|
Business Summary
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries.
View More